tetano
Editor, Senior Moderator
IDCases
. 2021;26:e01344.
doi: 10.1016/j.idcr.2021.e01344. Epub 2021 Nov 17.
Immune thrombocytopenia relapse post covid-19 vaccine in young male patient
Hana Qasim[SUP] 1 [/SUP], Elrazi Ali[SUP] 2 [/SUP], Mohamad A Yassin[SUP] 1 [/SUP]
Affiliations
Abstract
Immune thrombocytopenic purpura (ITP) is a blood disorder in which antibodies coating platelets cause platelets destruction in the spleen with resultant low platelets count and an increased tendency for bleeding. Coronavirus disease 2019 (COVID-19) is an illness caused by SARS-COV2; it was first identified in December/2019; though it mainly affects the respiratory system, multisystemic complications are identified. Several ITP cases post mRNA SARS-CoV-2 vaccines were reported, and different pathophysiology theories about the underlying pathophysiology were discussed, but only a few ITP relapse cases have been reported so far. We present a 28-year-old Asian male, a known patient of ITP and in partial remission for eighteen months, who presented to the emergency department with ITP relapse (platelets count of 1 × 10^3 /µL), four days after receiving the second dose of Pfizer SARS-CoV-2 vaccine, which required treatment with intravenous immunoglobulins and dexamethasone. We further discuss the preferred approach in ITP patients who are willing to receive the COVID-19 vaccine.
Keywords: ITP; Pfizer vaccine; Relapse; SARS-CoV-2.
. 2021;26:e01344.
doi: 10.1016/j.idcr.2021.e01344. Epub 2021 Nov 17.
Immune thrombocytopenia relapse post covid-19 vaccine in young male patient
Hana Qasim[SUP] 1 [/SUP], Elrazi Ali[SUP] 2 [/SUP], Mohamad A Yassin[SUP] 1 [/SUP]
Affiliations
- PMID: 34804803
- PMCID: PMC8595970
- DOI: 10.1016/j.idcr.2021.e01344
Abstract
Immune thrombocytopenic purpura (ITP) is a blood disorder in which antibodies coating platelets cause platelets destruction in the spleen with resultant low platelets count and an increased tendency for bleeding. Coronavirus disease 2019 (COVID-19) is an illness caused by SARS-COV2; it was first identified in December/2019; though it mainly affects the respiratory system, multisystemic complications are identified. Several ITP cases post mRNA SARS-CoV-2 vaccines were reported, and different pathophysiology theories about the underlying pathophysiology were discussed, but only a few ITP relapse cases have been reported so far. We present a 28-year-old Asian male, a known patient of ITP and in partial remission for eighteen months, who presented to the emergency department with ITP relapse (platelets count of 1 × 10^3 /µL), four days after receiving the second dose of Pfizer SARS-CoV-2 vaccine, which required treatment with intravenous immunoglobulins and dexamethasone. We further discuss the preferred approach in ITP patients who are willing to receive the COVID-19 vaccine.
Keywords: ITP; Pfizer vaccine; Relapse; SARS-CoV-2.